Literature DB >> 10209273

Multiple folding pathways for heterologously expressed human prion protein.

G S Jackson1, A F Hill, C Joseph, L Hosszu, A Power, J P Waltho, A R Clarke, J Collinge.   

Abstract

Human PrP (residues 91-231) expressed in Escherichia coli can adopt several conformations in solution depending on pH, redox conditions and denaturant concentration. Oxidised PrP at neutral pH, with the disulphide bond intact, is a soluble monomer which contains 47% alpha-helix and corresponds to PrPC. Denaturation studies show that this structure has a relatively small, solvent-excluded core and unfolds to an unstructured state in a single, co-operative transition with a DeltaG for folding of -5.6 kcal mol-1. The unfolding behaviour is sensitive to pH and at 4.0 or below the molecule unfolds via a stable folding intermediate. This equilibrium intermediate has a reduced helical content and aggregates over several hours. When the disulphide bond is reduced the protein adopts different conformations depending upon pH. At neutral pH or above, the reduced protein has an alpha-helical fold, which is identical to that observed for the oxidised protein. At pH 4 or below, the conformation rearranges to a fold that contains a high proportion of beta-sheet structure. In the reduced state the alpha- and beta-forms are slowly inter-convertible whereas when oxidised the protein can only adopt an alpha-conformation in free solution. The data we present here shows that the human prion protein can exist in multiple conformations some of which are known to be capable of forming fibrils. The precise conformation that human PrP adopts and the pathways for unfolding are dependent upon solvent conditions. The conditions we examined are within the range that a protein may encounter in sub-cellular compartments and may have implications for the mechanism of conversion of PrPC to PrPSc in vivo. Since the conversion of PrPC to PrPSc is accompanied by a switch in secondary structure from alpha to beta, this system provides a useful model for studying major structural rearrangements in the prion protein.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10209273     DOI: 10.1016/s0167-4838(99)00038-2

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  38 in total

1.  Three-dimensional domain swapping in the folded and molten-globule states of cystatins, an amyloid-forming structural superfamily.

Authors:  R A Staniforth; S Giannini; L D Higgins; M J Conroy; A M Hounslow; R Jerala; C J Craven; J P Waltho
Journal:  EMBO J       Date:  2001-09-03       Impact factor: 11.598

2.  From conversion to aggregation: protofibril formation of the prion protein.

Authors:  Mari L DeMarco; Valerie Daggett
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

3.  Influence of pH on the human prion protein: insights into the early steps of misfolding.

Authors:  Marc W van der Kamp; Valerie Daggett
Journal:  Biophys J       Date:  2010-10-06       Impact factor: 4.033

4.  Recombinant prion protein does not possess SOD-1 activity.

Authors:  Samantha Jones; Mark Batchelor; Daljit Bhelt; Anthony R Clarke; John Collinge; Graham S Jackson
Journal:  Biochem J       Date:  2005-12-01       Impact factor: 3.857

5.  Selective incorporation of polyanionic molecules into hamster prions.

Authors:  James C Geoghegan; Pablo A Valdes; Nicholas R Orem; Nathan R Deleault; R Anthony Williamson; Brent T Harris; Surachai Supattapone
Journal:  J Biol Chem       Date:  2007-10-16       Impact factor: 5.157

6.  The intrinsic helical propensities of the helical fragments in prion protein under neutral and low pH conditions: a replica exchange molecular dynamics study.

Authors:  Xiaoliang Lu; Juan Zeng; Ya Gao; John Z H Zhang; Dawei Zhang; Ye Mei
Journal:  J Mol Model       Date:  2013-09-17       Impact factor: 1.810

7.  Misfolded PrP impairs the UPS by interaction with the 20S proteasome and inhibition of substrate entry.

Authors:  Pelagia Deriziotis; Ralph André; David M Smith; Rob Goold; Kerri J Kinghorn; Mark Kristiansen; James A Nathan; Rina Rosenzweig; Dasha Krutauz; Michael H Glickman; John Collinge; Alfred L Goldberg; Sarah J Tabrizi
Journal:  EMBO J       Date:  2011-07-08       Impact factor: 11.598

8.  PrP-grafted antibodies bind certain amyloid β-protein aggregates, but do not prevent toxicity.

Authors:  David Mengel; Wei Hong; Grant T Corbett; Wen Liu; Alexandra DeSousa; Laura Solforosi; Cheng Fang; Matthew P Frosch; John Collinge; David A Harris; Dominic M Walsh
Journal:  Brain Res       Date:  2018-12-26       Impact factor: 3.252

9.  Purification and Fibrillation of Full-Length Recombinant PrP.

Authors:  Natallia Makarava; Regina Savtchenko; Ilia V Baskakov
Journal:  Methods Mol Biol       Date:  2017

Review 10.  The consequences of pathogenic mutations to the human prion protein.

Authors:  Marc W van der Kamp; Valerie Daggett
Journal:  Protein Eng Des Sel       Date:  2009-07-14       Impact factor: 1.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.